Skip to main content
OpenTrials
Completed

NCT Number: NCT06063096

Gastrointestinal Tolerance of D-allulose in Children

D-allulose, a low-calorie sugar, provides an attractive alternative to sucrose and added sugars in products. This study aimed to verify the tolerance of d-allulose in children, in doses that are Generally Recognised As Safe (GRAS) and below maximum tolerable levels on g/kg basis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

6 year–8 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy children of 6 to 8 years of age
  • Weight-for-age between the 5th and the 90th percentile as per the Centre for Disease Control and Prevention Growth Charts
  • Accustomed to having lunch between 12.00 pm and 2.30 pm
  • Routinely had up to 3 bowel movements per day or as few as 3 bowel movements per week
  • Were able to drink 120 ml within 30 minutes
  • With parents willing to continue their child's normal food and beverage intake and physical activity throughout the duration of the study
  • With parents willing and able to attend for all 7 visits

Exclusion criteria

  • Any major trauma or surgical event within the 3 months prior to screening
  • History or presence of clinically significant endocrine or GI disorder
  • Functional GI Disorders in accordance with Rome III Diagnostic Questionnaire for Paediatric Functional GI Disorders
  • More than 1 loose stool in the 48 hours preceding dosing, that met a Type 6 or Type 7 description on the Bristol Stool Chart
  • Use of any prescription medication, including antibiotics, laxatives and steroids
  • Regular GI complaints, such as stomach upsets, diarrhoea, constipation, flatulence, abdominal colic
  • Known intolerance or sensitivity to any of the study products, abdominal or anorectal surgery
  • Psychiatric disorders, anxiety, and depression
  • Lactose intolerance
  • Use of supplements that may have affected GI system including laxatives, fibre, and iron supplements
  • Exposure to any non-registered drug product within 30 days prior to screening visit.

Treatment and study plan

D-allulose

Dietary Supplement

Fruit-flavoured drink with d-allulose at 2 dosages

Placebo

Dietary Supplement

Fruit-flavoured drink with high fructose corn syrup

Primary outcomes

  1. Difference in the number of participants experiencing at least one stool that met a Type 6 or Type 7 description on the Bristol Stool Chart, within 24 hours after study product intake

    Time frame: within 24 hours after study product intake

    Difference in the number of subjects experiencing at least one stool that met a Type 6 or Type 7 description on the Bristol Stool Chart

Secondary outcomes

  1. Number of subjects who experienced at least one loose or watery stool that met a Type 6 or Type 7 description on the Bristol Stool Chart

    Time frame: in a 24-hour period post-consumption of intervention

    Stool frequency, measured as the number of subjects who experienced at least one loose or watery stool that met a Type 6 or Type 7 description on the Bristol Stool Chart

  2. Frequency of the GI symptom event and frequency of participants reporting GI symptoms events by the severity and causality (i.e., related, not related) for each treatment group recorded at Visits 3, 5 and 7, for pre- and post-dose administration

    Time frame: in the 24-hour period post-consumption

    Report common gastrointestinal symptoms including abdominal pain, bloating, cramping, abdominal rumbling, excess flatus, and and nausea associated with d-allulose consumption. These were reported as the frequency of the event and frequency of participants reporting events by the severity and causality (i.e., related, not related) for each treatment group recorded at Visits 3, 5 and 7, for pre- and post-dose administration. The severity of the event was categorized in three levels (mild, moderate, severe).

Sponsors and collaborators

Lead sponsor

Tate & Lyle

Industry

Registry information

Official study title

Gastrointestinal Tolerance of D-allulose in Children: an Acute, Randomised, Double-blind, Placebo-controlled, Cross-over Study

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Oct 2, 2023
Registry last updated
Oct 2, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.